Study of Ibrutinib for Patients with Chronic Lymphocytic Leukemia and TP53 Mutations

2 1 1 1

What is this study about?

This clinical trial is focused on studying Chronic Lymphocytic Leukemia (CLL), a type of cancer that affects the blood and bone marrow. The study is specifically looking at patients with CLL who have certain genetic changes called TP53 aberrations. These changes can affect how the disease progresses. The treatment being tested in this study is a medication called ibrutinib, which is taken orally. Ibrutinib is designed to help manage CLL by targeting specific pathways in cancer cells.

The purpose of the study is to understand how the genetic makeup of the cancer cells changes over time in patients with CLL who have these TP53 mutations. Participants in the study will receive ibrutinib as their first treatment for CLL. The study will monitor the patients at various time points, starting from the beginning of the treatment and continuing at weeks 2, 4, 12, 24, 48, 72, and 96, and then every year until the study ends or the disease progresses.

Throughout the study, researchers will observe how the size of the TP53 mutated subclones, which are small groups of cancer cells with these specific mutations, changes in response to the treatment. This information will help in understanding the effectiveness of ibrutinib in managing CLL with TP53 aberrations and may provide insights into better treatment strategies for this condition in the future.

1 joining the study

Participation begins after meeting specific criteria, including being 18 years or older, having a documented diagnosis of chronic lymphocytic leukemia (CLL), and showing progressive disease that requires treatment.

Eligibility also requires a negative test for certain viral infections and, for some participants, evidence of a small subclone carrying a TP53 deletion.

2 baseline assessment

Initial assessments are conducted to establish a baseline for the study. This includes evaluating the size of the TP53 mutated subclone using specific tests.

3 treatment with <b>ibrutinib</b>

Ibrutinib is administered orally. The dosage and frequency are determined by the study protocol and are designed to treat CLL effectively.

The treatment aims to observe changes in the clonal composition of the disease over time.

4 follow-up assessments

Regular assessments are scheduled at weeks 2, 4, 12, 24, 48, 72, and 96, and then annually until the study concludes or disease progression occurs.

These assessments focus on monitoring the size of the TP53 mutated subclone compared to the baseline.

5 end of study

The study is estimated to conclude by July 31, 2027. Participants will continue to be monitored until this date or until disease progression is observed.

Who Can Join the Study?

Must be 18 years or older.
Must have a documented diagnosis of Chronic Lymphocytic Leukemia (CLL) according to specific guidelines from 2008.
Must not have received any previous treatment for CLL, except for steroid treatment used to manage autoimmune issues.
Must have a negative test for certain hepatitis viruses:
- Negative for HBsAg (a marker for hepatitis B infection) and HBcAb (another marker for hepatitis B), or if positive for HBcAb, must be negative for HBV DNA (a test for active hepatitis B virus) using a specific method called quantitative PCR.
- Negative for HCV antibody (a marker for hepatitis C infection), or if positive, must be negative for HCV RNA (a test for active hepatitis C virus).
Must have progressive disease that requires treatment according to the 2008 guidelines for CLL.
For a specific group in the study (Cohort 2), there must be evidence of a small group of cells (less than 20%) with a TP53 deletion detected by a method called FISH (a test to look for specific genetic changes).

Who Cannot Join the Study?

Patients who do not have Chronic Lymphocytic Leukemia (CLL).
Patients without TP53 mutations. These are specific changes in a gene that can affect how cells grow.
Patients who are not in the age range specified for the study.
Patients who are not experiencing progression of their CLL. This means their disease is not getting worse.
Patients who are part of a vulnerable population, which means they might need special protection or care.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Azienda Ospedaliero Universitaria Di Sassari	Sassari	Italy

Other Sites

Site Name	City	Country
Hospital Santa Maria Della Misericordia	Perugia	Italy
Azienda Socio Sanitaria Territoriale Dei Sette Laghi	Varese	Italy
Ospedale San Raffaele S.r.l.	Milan	Italy
Fondazione IRCCS Policlinico San Matteo	Pavia	Italy
Azienda Ospedaliero-Universitaria Maggiore Della Carita	Novara	Italy
Fondazione I.R.C.C.S. Istituto Neurologico Besta	Milan	Italy

Trial status

Country	Status	Recruitment Start
Italy	Not recruiting	01.11.2017

Trial locations

Investigated drugs:

Ibrutinib

Ibrutinib is a medication used in this clinical trial to treat patients with chronic lymphocytic leukemia (CLL) who have specific genetic changes known as TP53 mutations. It works by blocking a protein that helps cancer cells grow and survive, which may slow down or stop the progression of the disease.

Investigated diseases:

Chronic lymphocytic leukaemia

Chronic Lymphocytic Leukemia (CLL) – Chronic Lymphocytic Leukemia is a type of cancer that affects the blood and bone marrow. It is characterized by the production of an excessive number of abnormal lymphocytes, a type of white blood cell. These abnormal cells accumulate over time, crowding out healthy blood cells and impairing the immune system. CLL typically progresses slowly, and many individuals may not experience symptoms for years. As the disease advances, it can lead to symptoms such as fatigue, swollen lymph nodes, and frequent infections. The progression of CLL can vary greatly among individuals, with some experiencing a more aggressive form of the disease.

Trial ID:

2024-514823-41-00

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study of Ibrutinib for Patients with Chronic Lymphocytic Leukemia and TP53 Mutations

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?